Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed OTC Markets Other stock markets 11:14:35 2021-10-05 EDT			5-day change	1st Jan Change
4.510 ^USD	-5.65%		-2.45%	-

07-13	Cosmos Health Inc. And Libytec Pharmaceutical S.A. Enters Distribution And Promotion Agreement For DIABIT-IS X In Greece	CI
07-13	Cosmos Health, Libytec Enter Distribution Deal for Diabetes Drug	MT

Market Cap	10.86M 9.54M 8.87M 8.14M 15.3M 1.05B 15.53M 105M 41.16M 514M 40.78M 39.9M 1.78B	P/E 2026 *	20x	P/E 2027 *	2.86x
Enterprise Value	10.86M 9.54M 8.87M 8.14M 15.3M 1.05B 15.53M 105M 41.16M 514M 40.78M 39.9M 1.78B	EV / Sales 2026 *	0.13x	EV / Sales 2027 *	0.1x
Free-Float	65.92%	Yield 2026 *	-	Yield 2027 *	-

07-13	Cosmos Health Inc. And Libytec Pharmaceutical S.A. Enters Distribution And Promotion Agreement For DIABIT-IS X In Greece	CI
07-13	Cosmos Health, Libytec Enter Distribution Deal for Diabetes Drug	MT
07-10	Cosmos Health Inc. Launches Subscription-Based Purchasing Model for Its Proprietary Consumer Health Brands	CI
07-10	Cosmos Health Launches Subscription-Based Purchasing Model	MT
07-07	Cosmos Health Inc. Provides Preliminary Revenue Guidance for the Second Quarter and First Half 2026	CI
07-02	Cosmos Health Expands Share Buyback to 3.4 Million Shares	MT
06-30	Cosmos Health Inc. announces an Equity Buyback for $5 million worth of its shares.	CI
06-29	Cosmos Health Inc. authorizes a Buyback Plan.	CI
06-26	Cosmos Health Signs Qatar Distribution Deal With IMC	MT
06-26	Cosmos Health Inc. Signs Distribution Agreement with International Medical Company, and Secures Initial Purchase Order of 31,000 Sky Premium Life Units	CI
06-23	Cosmos Health to Deploy AI-Powered Call Center at Pharma Distribution Unit	MT
06-18	Cosmos Health Inc. Expands AI Automation and Facility Capacity	CI
06-17	Cosmos Health Launches Premium Korean-Developed Collagen-Based Skincare Brand in the United States	CI

07-20	Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units	GL
07-17	Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases	GL
07-16	Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases	GL
07-15	Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases	GL
07-14	Cosmos Health Share Buyback Expands to 4.49 Million Shares; Continues Open Market Repurchases	GL

Cosmos Holdings Inc. Stock OTC Markets

Stocks

COSM

US2214131078

Pharmaceuticals

Valuation: Cosmos Holdings Inc.

Latest news : Cosmos Holdings Inc.

Press Releases: Cosmos Holdings Inc.

News in other languages: Cosmos Holdings Inc.

Quotes and Performance

Managers and Directors: Cosmos Holdings Inc.

Pharmaceuticals Wholesale

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

24-11-29	Dalla farmaceutica al fitness: la corsa all'oro del bitcoin - Crypt On It
24-11-28	De la farmacia al gimnasio: la fiebre del bitcoin - Crypto Recap
22-12-05	Pelè non è in cure palliative - figlia
22-12-01	BASF : lance un agent nacrant naturel à base de cire

Manager	Title	Age	Since
Grigorios Siokas CEO	Chief Executive Officer	60	2016-02-25
Georgios Terzis DFI	Director of Finance/CFO	43	2020-11-10
Nikolaos Bardakis COO	Chief Operating Officer	56	2023-01-31

Director	Title	Age	Since
Demetrios Demetriades BRD	Director/Board Member	58	2014-01-12
Grigorios Siokas CHM	Chairman	60	2016-02-25
John Hoidas BRD	Director/Board Member	59	2016-11-17

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
COSMOS HOLDINGS INC.	-5.65%	-2.45%	-	-	10.86M
MCKESSON CORPORATION	+1.99%	-0.06%	+18.13%	+108.25%	98.45B
CARDINAL HEALTH, INC.	+0.91%	-0.21%	+45.11%	+147.11%	53.41B
SIGMA HEALTHCARE LIMITED	+0.35%	-2.39%	-0.69%	+266.67%	22.84B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	-1.27%	-1.38%	-13.70%	-21.17%	8.13B
HUADONG MEDICINE CO., LTD	-5.96%	-5.05%	-33.11%	-36.38%	7.4B
SINOPHARM GROUP CO. LTD.	+0.83%	-3.46%	-13.57%	-30.57%	6.7B
H. LUNDBECK A/S	-0.80%	-1.73%	+20.00%	+29.04%	6.17B
GALENICA AG	-0.52%	-2.75%	-1.14%	+22.46%	5.29B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-0.99%	-1.96%	-7.05%	-9.06%	3.69B
Average	-1.06%	-3.01%	+1.55%	+52.93%	23.57B
Weighted average by Cap.	+0.95%	-1.15%	+18.02%	+114.22%

	2026 *	2027 *
Net sales	84.3M 74.04M 68.86M 63.18M 119M 8.12B 121M 818M 319M 3.99B 316M 310M 13.8B	111M 97.32M 90.5M 83.05M 156M 10.67B 158M 1.07B 420M 5.25B 416M 407M 18.14B
Net income	-	-
Net Debt	-	-